Navigation Links
Ironwood and Collaborators Present Preclinical Data Demonstrating That Cyclic GMP Alleviates Intestinal Pain
Date:10/6/2008

Vice President and Chief Medical Officer at Ironwood.

"These novel findings provide valuable insight into the possible role of cGMP in alleviating intestinal pain and may explain the reduction in intestinal pain observed in patients with IBS-C treated with linaclotide in our Phase 2b studies," said Mark Currie, Ph.D., Senior Vice President, R&D and Chief Scientific Officer at Ironwood.

About Linaclotide

Linaclotide is a first-in-class compound currently being evaluated for the treatment of IBS-C, chronic constipation (CC), and other gastrointestinal disorders. Linaclotide was designed to exert its effect on the intestine with minimal systemic exposure. Linaclotide is an agonist of guanylate cyclase type-C, a receptor found on the lining of the intestine. Linaclotide demonstrated proof of concept in a comprehensive Phase 2b program, comprised of two clinical studies in over 700 patients with either IBS-C or CC. In patients with IBS-C, linaclotide reduced abdominal pain and relieved constipation-the hallmarks of the condition-throughout the 12-week treatment period. In patients with CC, linaclotide reduced constipation throughout the 4-week study period. Linaclotide was well tolerated at all doses in both Phase 2b studies, with the most common adverse event being diarrhea. A United States patent covering linaclotide composition of matter expires in 2025. In September 2007, Ironwood and Forest Laboratories entered into a 50/50 collaboration to co-develop and co-promote linaclotide in the United States. Ironwood retains exclusive rights to linaclotide outside of North America.

About Irritable Bowel Syndrome (IBS)

One out of six adults in developed countries suffers from IBS, a chronic condition marked by abdominal pain and disturbed bowel function. IBS accounts for 12% of adult visits to primary care physicians and is the most common disorder diagnosed by gastroenterologists. Healthcare costs associated with IBS exceed $25 billion ann
'/>"/>

SOURCE Ironwood Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results
2. Ironwood and Forest to Present Positive Data From Linaclotide Phase 2b IBS-C Study at ACG Annual Scientific Conference
3. Ironwood Raises $50 Million to Advance Linaclotide Through Phase 3
4. Novel PCT Method Unveiled by Pressure BioSciences, Inc. and Collaborators at the Harvard School of Public Health
5. Rosetta Genomics and Collaborators Identify MicroRNAs That Can Accurately Discriminate Between Primary and Metastatic Tumors in the Brain
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
8. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
11. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... Colo. , Dec. 15, 2014  The Government of ... collaboration of AABB, Global Blood Fund (GBF) and Terumo BCT to ... , as well as provide long-term health system capacity to ... Facts: , The Ghanaian Ebola Readiness and Resilience Initiative ... Ghana,s preparations for the possible arrival of the ...
(Date:12/13/2014)... Research and Markets ( http://www.researchandmarkets.com/research/2r6bmg/drug_injection ... "Drug Injection Devices to 2020" report to ... As new drugs become available ... health conditions, drug developers have increasingly pursued packaging ... and increase the efficiency and reliability with which ...
(Date:12/13/2014)... , Dec. 12, 2014 HudsonAlpha ... the HiSeq X Ten sequencing system manufactured by ... HudsonAlpha to produce and analyze genomic data faster ... from the Institute,s commitment to research programs for ... HiSeq X Ten provides unprecedented capacity, speed and ...
Breaking Medicine Technology:Government of Ghana Endorses Collaboration to Combat Ebola Epidemic 2Government of Ghana Endorses Collaboration to Combat Ebola Epidemic 3Government of Ghana Endorses Collaboration to Combat Ebola Epidemic 4Government of Ghana Endorses Collaboration to Combat Ebola Epidemic 5Government of Ghana Endorses Collaboration to Combat Ebola Epidemic 6Drug Injection Devices to 2020 2Drug Injection Devices to 2020 3Drug Injection Devices to 2020 4HudsonAlpha announces purchase of Illumina HiSeq X Ten sequencing system 2HudsonAlpha announces purchase of Illumina HiSeq X Ten sequencing system 3
... Overactive Bladder Treatment for... -- ARDEE, Ireland, Oct. 18 ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... { var s = ,; var first_result; // Results are keyed by longUrl, so we need to grab the ...
... 2010 ... ... ... Results are keyed by longUrl, so we need to grab the first one. for (var r in data.results) { ...
Cached Medicine Technology:Warner Chilcott Completes Acquisition of U.S. Rights to Enablex® Overactive Bladder Treatment for $400 Million in Cash 2Warner Chilcott Completes Acquisition of U.S. Rights to Enablex® Overactive Bladder Treatment for $400 Million in Cash 3Warner Chilcott Completes Acquisition of U.S. Rights to Enablex® Overactive Bladder Treatment for $400 Million in Cash 4Warner Chilcott Completes Acquisition of U.S. Rights to Enablex® Overactive Bladder Treatment for $400 Million in Cash 5Warner Chilcott Completes Acquisition of U.S. Rights to Enablex® Overactive Bladder Treatment for $400 Million in Cash 6Warner Chilcott Completes Acquisition of U.S. Rights to Enablex® Overactive Bladder Treatment for $400 Million in Cash 7Warner Chilcott Completes Acquisition of U.S. Rights to Enablex® Overactive Bladder Treatment for $400 Million in Cash 8Warner Chilcott Completes Acquisition of U.S. Rights to Enablex® Overactive Bladder Treatment for $400 Million in Cash 9Visonic Technologies Announces the Immediate Availability of its Elpas Door Kit, an 'All-in-One Starter Kit' Packaged With Everything Required to Install a Single-Door Wandering Patient and Resident Protection Solution 2Visonic Technologies Announces the Immediate Availability of its Elpas Door Kit, an 'All-in-One Starter Kit' Packaged With Everything Required to Install a Single-Door Wandering Patient and Resident Protection Solution 3Visonic Technologies Announces the Immediate Availability of its Elpas Door Kit, an 'All-in-One Starter Kit' Packaged With Everything Required to Install a Single-Door Wandering Patient and Resident Protection Solution 4Visonic Technologies Announces the Immediate Availability of its Elpas Door Kit, an 'All-in-One Starter Kit' Packaged With Everything Required to Install a Single-Door Wandering Patient and Resident Protection Solution 5Visonic Technologies Announces the Immediate Availability of its Elpas Door Kit, an 'All-in-One Starter Kit' Packaged With Everything Required to Install a Single-Door Wandering Patient and Resident Protection Solution 6Visonic Technologies Announces the Immediate Availability of its Elpas Door Kit, an 'All-in-One Starter Kit' Packaged With Everything Required to Install a Single-Door Wandering Patient and Resident Protection Solution 7Visonic Technologies Announces the Immediate Availability of its Elpas Door Kit, an 'All-in-One Starter Kit' Packaged With Everything Required to Install a Single-Door Wandering Patient and Resident Protection Solution 8
(Date:12/15/2014)... 15, 2014 Main Street Dental Team ... weighing in on a new study providing evidence on ... oral hygiene of children. , Sufficient enough evidence already ... as pop or juice drinks, with the onset of ... is whether drinks listed as 100% fruit juice, meaning ...
(Date:12/15/2014)... SIMpalm, a leading mobile app ... iPhone for its client, which allows users to keep ... specialized in finding the right wine. At the ... combined sensory, chemistry and wine information. All this information ... fingerprint.” Those wines that are close counterparts to one ...
(Date:12/15/2014)... MA (PRWEB) December 15, 2014 ... management solutions, announced today that it has received ... Quality Assurance (NCQA) for its Disease Management (DM) ... pulmonary disease (COPD), coronary heart disease and diabetes. ... from NCQA for Health Dialog’s Disease Management (DM) ...
(Date:12/15/2014)... pilots process visual information more efficiently than less experienced ... landings, a new study shows. Landing is one ... and 36 percent of all airplane crashes and 25 ... landing. Researchers monitored the brain activity of eight ... were at the controls of a flight simulator. As ...
(Date:12/15/2014)... SIMSBURY, CT (PRWEB) December 15, 2014 ... in the prestigious Women World Awards in the category ... of a gold award for her weekly career blog ... and practical advice to help professionals elevate their talent ... Her blog, named after her book Networking Ahead ...
Breaking Medicine News(10 mins):Health News:Main Street Dental Team, Unionville’s Most Innovative Dental Clinic, Comments on New Study Relating Pure Fruit Juice to Poor Oral Hygiene 2Health News:Use WinMatch Connect App to Keep Track of Wines You Like 2Health News:Health Dialog Receives NCQA Accreditation for Disease Management Programs 2Health News:Study Shows Why Expert Pilots Are Experts 2Health News:Kathy McAfee, America’s Marketing Motivator, Wins Best Blog from Women World Awards 2
... molecules found in certain plants appears to have a beneficial ... a new study conducted in mice. The study was led ... Medical Center. An article in the Journal of Cellular and ... of the senior authors of the study, is available to ...
... 7 /Xinhua-PRNewswire-FirstCall/ -- Linkwell,Corporation (Linkwell) (OTC Bulletin ... of healthcare related disinfectants in China,announced today ... Hi-Tech Company, Ltd., (LiKang Disinfectant) began training,and ... Olympics. The project,is sponsored by and under ...
... to Provide ... for Their Families, CHICAGO, May 7 Mother,s Day is ... gatherings and gifts,and to honor those who give so much to their families ... of those mothers who,live in poverty and need the assistance of programs offered ...
... Emory Winship Cancer Institute, ATLANTA, May 7 ... commitment of $50,000 to the Emory Winship Cancer ... southeast focused on,triple-negative breast cancer research. Dan Amos, ... president, made the personal donation,in honor of the ...
... The Female Health Company,(Amex: FHC ) today ... discuss its operating results for the second quarter of ... 14, 2008. The Company plans to,report its second quarter ... and other interested parties may participate in the,conference call ...
... Highlighted, TAMPA, Fla., May 7 Acute pain ... than 25 million,Americans are said to experience acute pain ... a recent study estimated that 42 percent of U.S.,hospital ... Seven clinical presentations on tapentadol immediate release (IR),tablets for ...
Cached Medicine News:Health News:Linkwell Corporation Begins Training and Licensing Beijing Olympics Disinfection Teams 2Health News:Linkwell Corporation Begins Training and Licensing Beijing Olympics Disinfection Teams 3Health News:Linkwell Corporation Begins Training and Licensing Beijing Olympics Disinfection Teams 4Health News:Catholic Charities Calls for Increased Support of Mothers in Need: 2Health News:Aflac CEO Funds Breast Cancer Symposium in Honor of Company's African-American Female Employees 2Health News:Aflac CEO Funds Breast Cancer Symposium in Honor of Company's African-American Female Employees 3Health News:The Female Health Company Schedules Second Quarter Conference Call for May 14, 2008 2Health News:Seven Clinical Presentations on Tapentadol Immediate Release for Acute Pain to Be Featured at 2008 American Pain Society Annual Meeting 2Health News:Seven Clinical Presentations on Tapentadol Immediate Release for Acute Pain to Be Featured at 2008 American Pain Society Annual Meeting 3Health News:Seven Clinical Presentations on Tapentadol Immediate Release for Acute Pain to Be Featured at 2008 American Pain Society Annual Meeting 4
... in the field of Urodynamics, Albyn Medical recognised ... new chair is manufactured from the highest quality ... can be improved considerably if the patient is ... this aspect was given a high priority in ...
The Triage Drugs of Abuse Panel is the leading rapid drug screen used by U.S. hospitals. The Triage Drugs of Abuse Panel is a small, handheld urine test that provides qualitative results for up to n...
... The Advanced Model 3900 Multi-Sample ... for laboratories processing moderate to high ... industry-preferred method of freezing-point technology for ... combined with high, continuous throughput, the ...
... The Advanced® 2020 Multi-Sample Osmometer provides ... industrial, and research settings. These results ... freezing-point method, which determines total concentration. ... on-board data management, automated sample handling, ...
Medicine Products: